ADH-6 TFA, a tripyridylamide compound, effectively disrupts the self-assembly of the aggregation-nucleating subdomain of mutant p53 DBD, thereby targeting and disassociating mutant p53 aggregates in human cancer cells. This action restores the transcriptional activity of p53, resulting in cell cycle arrest and apoptosis. Consequently, ADH-6 TFA holds potential for cancer research [1].
Molecular Weight:
754.67
Formula:
C31H37F3N8O11
Target:
MDM-2/p53|||Apoptosis|||Others
* VAT and and shipping costs not included. Errors and price changes excepted
